European Journal of Pharmaceutics and Biopharmaceutics, Год журнала: 2024, Номер unknown, С. 114531 - 114531
Опубликована: Окт. 1, 2024
Язык: Английский
European Journal of Pharmaceutics and Biopharmaceutics, Год журнала: 2024, Номер unknown, С. 114531 - 114531
Опубликована: Окт. 1, 2024
Язык: Английский
Journal of Chemistry, Год журнала: 2024, Номер 2024, С. 1 - 21
Опубликована: Май 31, 2024
Absorption of free radicals in the body cannot be done by antioxidant compounds originating from human body, so exogenous antioxidants are required to help their natural action. Oxidative stress can caused an imbalance radical inhibitors and accumulation that enter cellular structures. Synthetic found external not primary choice because they harmful carcinogenic. Therefore, using ingredients provides a necessary alternative constructing novel antioxidants. Recent studies have highlighted critical analysis evaluation flavonoids unique class secondary metabolites plants used communities as traditional therapeutics with proven bioactivity. This could support new discoveries based on various herbal medicines addition, functional effectiveness against radicals. In this review, there several strengths discussion. First, study takes comprehensive approach covering aspects, including properties sources radicals, oxidative relation different diseases, defense mechanisms, specific mechanisms flavonoids. Second, focus antioxidants, especially flavonoids, also discussion about clinical applications studies, limitations, global perspectives, future research directions become references selection medicines. But, constraints should considered when interpreting findings review. mechanism is only discussed general one example compound (flavonoid) has potential antioxidant. lack regarding relationship between diseases Third, limited number investigated some discussed.
Язык: Английский
Процитировано
49Life Sciences, Год журнала: 2024, Номер 344, С. 122566 - 122566
Опубликована: Март 17, 2024
Язык: Английский
Процитировано
12Inorganic Chemistry Communications, Год журнала: 2025, Номер unknown, С. 113917 - 113917
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
1Seminars in Oncology Nursing, Год журнала: 2025, Номер unknown, С. 151809 - 151809
Опубликована: Фев. 1, 2025
Anxiety and depression are common symptoms in oncology patients undergoing chemotherapy. Study purpose was to evaluate for differences severity of (ie, fatigue, energy, sleep disturbance, cognitive function, pain) quality life (QOL) outcomes among three subgroups outpatients with distinct joint anxiety profiles. Oncology (N = 1328) completed measures state depression, six times over two cycles Latent profile analysis done identify AND Patients trait anxiety, morning evening pain, as well generic disease-specific QOL at enrollment. Differences the classes symptom scores were evaluated using parametric non-parametric tests. Three profiles identified named: Low Depression (57.5%, Both Low), Moderate (33.7%, Moderate), High (8.8%, High). All showed a "dose-response effect" worsened, all increased). Likewise, both general (except spiritual well-being) measures, decreased worsened. Compared classes, other reported lower well-being domain. More than 40% receiving chemotherapy experience moderate high levels depression. These report an extremely burden significant decrements domains QOL. Clinicians need perform comprehensive assessments during In addition, referrals targeted interventions needed manage multiple improve patients'
Язык: Английский
Процитировано
1Reproductive Toxicology, Год журнала: 2024, Номер 128, С. 108661 - 108661
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
3Life Sciences, Год журнала: 2025, Номер 362, С. 123378 - 123378
Опубликована: Янв. 7, 2025
Язык: Английский
Процитировано
0Psychopharmacology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 14, 2025
Язык: Английский
Процитировано
0Pharmaceuticals, Год журнала: 2025, Номер 18(1), С. 101 - 101
Опубликована: Янв. 15, 2025
Background/Objectives: In recent years the global incidence of cancer during pregnancy is rising, occurring in 1 out every 1000 pregnancies. this regard, most used chemotherapy drugs to treat are alkylating agents such as cyclophosphamide (Cp). Despite its great efficacy, has been associated with production oxidative stress and DNA damage, leading embryotoxicity, genotoxicity, teratogenicity developing conceptus. Therefore, study aimed investigate protective role phycobiliproteins (PBP) derived from Arthrospira maxima (spirulina) reducing Cp-induced embryotoxicity genotoxicity pregnant CD1 mice. Methods: Pregnant mice were divided into five groups: control, Cp 20 mg/kg, three doses PBP (50, 100, 200 mg/kg) + co-treatment. administered orally day 6 10.5 dpc, followed by a single intraperitoneal dose on dpc. Embryos collected at 12.5 dpc assess morphological development vascular alterations, while maternal damage was evaluated using micronucleus assays antioxidant enzyme activity plasma. Results: exhibited dose-dependent effect against damage. The mg/kg significantly reduced developmental abnormalities, micronucleated polychromatic erythrocytes, stress, (as evidenced increased SOD GPx activity). Conclusions: Phycobiliproteins effectively alterations embryos These findings highlight their potential complementary therapy mitigate teratogenic risks chemotherapy. Further research needed optimize dosing explore clinical applications.
Язык: Английский
Процитировано
0Metabolites, Год журнала: 2025, Номер 15(1), С. 60 - 60
Опубликована: Янв. 16, 2025
Purpose: Immunodeficiency conditions, which are characterized by reduced immune activity that promotes the development of chronic diseases, needed for efficient monitoring. A promising area monitoring and early diagnosis immunodeficiency diseases is determination metabolic biomarkers in blood. Methods: In this work, we identified a set lipid states performing high-performance liquid chromatography–high-resolution mass spectrometry (HPLC-HRMS) analysis blood plasma samples from mice processing them with bioinformatics approaches. Potential were selected through statistical further validated MS/MS. Conclusions: As result, 15 lipids confirmed as potential states. The can be studied serve targets diseases.
Язык: Английский
Процитировано
0Fluids and Barriers of the CNS, Год журнала: 2025, Номер 22(1)
Опубликована: Фев. 11, 2025
The choroid plexus (CP) has been recently implicated in the pathogenesis of neuropsychiatric manifestations systemic lupus erythematosus (NPSLE). Lupus patients demonstrate increased serum and cerebrospinal fluid (CSF) concentrations interleukin-6 (IL-6), which can disrupt vital blood-CSF barrier (B-CSFB) functions performed by CP. However, difficulty accessing this tissue largely precluded dynamic imaging or evaluation CP function vivo. In study, explant spheroids replicate functional structural properties B-CSFB were generated from 12 + week old female MRL/lpr (IL-6 wildtype; IL-6 WT) mice, knockout KO) congenic control MRL/mpj mice. derived WT mice found to synthesize secrete IL-6, similar vivo, whereas KO did not produce IL-6. Accumulation different fluorescent tracers within central CSF-like vacuole spheroids, modeling brain ventricles, was measured probe transcellular permeability, paracellular diffusion, clearance As shown blocking receptor comparing them signaling decreased spheroid methotrexate, a chemotherapeutic drug employed therapy lupus, lucifer yellow. This suppression occurred without altering epithelial morphology ultrastructure. Methotrexate yellow efflux occur through ATP-binding cassette (ABC) transporters, including BCRP MRP1. Cytoplasmic accumulation ABC-specific dye fluorescein diacetate also Pharmacologic inhibition either MRP1 sufficient recreate deficits observed spheroids. Moreover, expression significantly lower we establish, validate, apply model study lupus. Our results show that key cytokine NPSLE, potentially suppress CP-specific Therefore, could affect CSF inflammatory substrates (e.g., leukotrienes), would incite neurotoxicity promote progression NPSLE.
Язык: Английский
Процитировано
0